Statements (14)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:investigational_drug
gptkb:monoclonal_antibody |
| gptkbp:CASNumber |
2228327-73-7
|
| gptkbp:clinicalTrialPhase |
Phase 1
|
| gptkbp:developedBy |
gptkb:I-Mab_Biopharma
|
| gptkbp:intendedUse |
gptkb:cancer
|
| gptkbp:mechanismOfAction |
gptkb:immunotherapy
|
| gptkbp:otherName |
TJC4
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:target |
gptkb:CD47
|
| gptkbp:UNII |
6Q6K6Q6Q2F
|
| gptkbp:bfsParent |
gptkb:I-Mab_Biopharma
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
lemzoparlimab
|